Advertisement

TheBodyPRO.com Covers IAS 2015

News

HIV Treatment at High CD4 Counts Protects Against Both AIDS and Non-AIDS Events in the START Study: Overall and in Subgroup Analyses

July 20, 2015

 1  |  2  |  Next > 

Professor Jens Lundgren presenting ground-breaking results from the START study, with other key members of the study team, Abdel Babiker and Jim Neaton at lower right.

Professor Jens Lundgren presenting ground-breaking results from the START study, with other key members of the study team, Abdel Babiker and Jim Neaton at lower right.

The international START study produced headline news at IAS 2015 that confirm benefits from starting antiretroviral treatment (ART) at CD4 counts above 500 cells/mm3.

The study also reported no upper CD4 threshold that was protective against AIDS-related events, even thought the overall absolute risk of events was low.

The START study is notable for reporting results 18 months ahead of schedule, following a recommendation by the studies independent Data and Safety Monitoring Board (DSMB) in May that participants in the arm deferring ART until their CD4 count reached 350 cells/mm3 should be offered immediate treatment, and that follow-up should continue as planned for both arms.

The results were presented by Professor Jens Lundgren from University of Copenhagen on behalf of the START study team in two sessions at the conference: an opening plenary on the first day and the International AIDS Society members meeting later in the programme. [1, 2] The study was also simultaneously published online in the New England Journal of Medicine. [3]

This HTB report combines results from both IAS 2015 and NEJM paper.

Although preliminary findings were released on 27 May 2015 based on the dataset used for the DSMB decision, the expanded results cover three key areas:

  • The additional endpoints in the final dataset modifies the primary endpoint results by now finding that the reduction in non-AIDS events now reaches significance in favouring early ART. Back in May, this endpoint fell short of significance.
  • By providing new details about the AIDS and non-AIDS events seen in each arm and still finding that AIDS events drove the primary results and occurred at high CD4 counts.
  • That in subgroup analyses, early ART was consistently protective for all key baseline and demographic subgroups. It is important to stress that benefits from the study were not just for people with highest risks.


Advertisement

Methods and Baseline Characteristics

From December 2009 to December 2013, START randomised 4685 HIV positive treatment-naive adults with CD4 counts >500 cells/mm3 to either an immediate (IMM) or deferred (DEF) ART, with the deferred group waited until the CD4 count reached 350 cells/mm3.

The combined primary endpoint included AIDS related and non-AIDS related complications including grade 4 events and deaths from any cause.

The study included 215 sites in 35 countries, equally divided between high and low/middle income countries. Baseline demographics have already been widely reported and published in online [4, 5] and included approximately 27% women, 55% MSM, and median age 36 years (IQR 29 to 44). Median CD4 and viral load were 651 cells/mm3 (IQR 584 to 765) and 12,700 copies/mL (IQR 3,000 to 43,000), respectively, with no significant differences between groups. At study entry, median time since HIV diagnosis was 1.0 years (IQR: 0.4 to 3.1).


Primary and Key Secondary Endpoint Results

Mean follow-up was 3.0 years (median 2.8; IQR 2.1 to 3.9) with 23% having greater than 4 years follow up. Endpoint results were available for 96% and 95% of the IMM and DEF groups respectively.

By 26 May 2015, 98% vs 48% of the IMM vs DEF participants had started ART (at median CD4 count of 651 vs 408 cells/mm3 respectively). Although ART in the study was provided free from a central repository, and included the choice of all or nearly all approved drugs, the majority of patients in both arms used tenofovir/FTC as background NRTIs (approximately 90%). Efavirenz was the most widely used third component, by 73% and 51% of the IMM vs DEF arms respectively, with atazanavir/r, darunavir/r, rilpivirine and raltegravir making up the majority of other combinations. The study reported high rates of viral suppression with 98% vs 97% of those on treatment having <200 copies/mL at month 12.

The final dataset includes a total of 140 primary endpoint events: 42 (1.8%) in the IMM arm vs 96 (4.1%) in the DEF arm, equivalent to rates of 0.60 vs 1.38 per 100 patient years, respectively. The hazard ratio (HR) for the composite primary endpoint was 0.43 (95% CI: 0.30 to 0.62), significantly in favour of the IMM group, p<0.001. Hazard ratios for other key secondary endpoints also significantly favoured the IMM group: 0.28 (95%CI: 0.15 to 0.50) for serious AIDS-related events (p<0.001) and 0.61 (95%CI: 0.38 to 0.97, p=0.04) for serious non-AIDS-related. There was no significant difference between groups for all cause mortality: HR 0.58 (95%CI: 0.28-1.17, p=0.13). See Table 1.


Table 1: Hazard Ratio (HR) of Primary and Key Secondary Endpoints
  IMM (N = 2326) DEF (N = 2359) HR
(95% CI)
P value
no. rate/100 PY no. rate/100 PY
Composite primary endpoint 42 0.60 96 1.38 0.43
(0.30 to 0.62)
<0.001
Secondary end points
Serious AIDS events 14 0.20 50 0.72 0.28
(0.15 to 0.50)
<0.001
Serious non-AIDS events 29 0.42 47 0.67 0.61
(0.38 to 0.97)
0.04
Death from any cause 12 0.17 21 0.30 0.58
(0.28 to 1.17)
0.13 NS

Key: IMM=immediate arm. DEF=deferred arm, HR=Hazard Ratio, NS=Non Significant.


Clinical Endpoints

An unexpected outcome in START is the degree to which AIDS events were more common at high CD4 counts than non-AIDS. Throughout the study it was expected that the greatest impact would be to reduce inflammation-related events. Also, consistent with the planned study design, only 4% of follow-up time in the deferred arm occurred at a CD4 count <350 cells/mm3 an accounted for only 5 primary events.

The most common events were cardiovascular disease (29% vs 15%), non-AIDS cancers (21% vs 19%) and tuberculosis (14% vs 20%) in the IMM vs DEF groups respectively.

Endpoints that were significantly reduced in the IMM group included tuberculosis (HR 0.29; 95%CI: 0.12 to 0.73), p=0.008) and Kaposi's Sarcoma (HR 0.09; 95%CI: (0.01 to 0.71, p=0.02) but not malignant lymphoma (p=0.07), non-AIDS cancers (p=0.09), cardiovascular disease (p=0.65), Grade 4 events (p=0.97), unscheduled hospitalisation (p=0.28) and combined Grade 4 event, unscheduled hospitalisation, or death from any cause (p=0.25). See Table 2.


Table 2: Other Important Clinical Secondary Endpoints
  IMM (N = 2326) DEF (N = 2359) HR (95% CI) P value
no. rate/100 PY no. rate/100 PY
Tuberculosis 6 0.09 20 0.28 0.29 (0.12 to 0.73) 0.008
Kaposi's sarcoma 1 0.01 11 0.16 0.09 (0.01 to 0.71) 0.02
Malignant lymphoma 3 0.04 10 0.14 0.30 (0.08 to 1.10) 0.07
Non-AIDS cancers 9 0.13 18 0.26 0.50 (0.22 to 1.11) 0.09
Cardiovascular disease 12 0.17 14 0.20 0.84 (0.39 to 1.81) 0.65
Grade 4 events 73 1.06 73 1.05 1.01 (0.73 to 1.39) 0.97
Unscheduled hospitalisation § 262 4.02 287 4.40 0.91 (0.77 to 1.08) 0.28
Grade 4 event, unscheduled hospitalisation, or death from any cause 283 4.36 311 4.78 0.91 (0.77 to 1.07) 0.25

§ This category excludes hospitalizations for AIDS-related illnesses.

 1  |  2  |  Next > 



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.